Yes please9 Aug 2022 23:10
PRTC1.53%5ShareA+A-Ad You May LikeDon't play this game if you are under 50 years old!Raid Shadow LegendsPlay NowMercedes May Have To Pay Customers £1,000sBond TurnerLearn MoreDoctor Reveals: A Simple Trick For Prostate ProblemsProstate HelpEmpty Mediterranean Cruise Cabins Cost Almost NothingCruise Deals | Search Ads by Taboola Sponsored Links SVB Securities analyst Thomas Smith maintained a Buy rating on PureTech Health (PRTC – Research Report) today and set a price target of $70.00. The company’s shares closed yesterday at $27.52.Smith covers the Healthcare sector, focusing on stocks such as Prometheus Biosciences, Celldex, and MannKind. According to TipRanks, Smith has an average return of -13.3% and a 33.17% success rate on recommended stocks.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PureTech Health with a $53.50 average price target.See Insiders’ Hot Stocks on TipRanks >>The company has a one-year high of $56.46 and a one-year low of $18.15. Currently, PureTech Health has an average volume of 6,021.TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on areas of growing scientific and technical insights that it believes are at an important inflection point, including the central nervous, gastrointestinal and immune systems, and the interactions and signaling between them. The company has a robust pipeline of advanced programs that are post-human proof of concept, focused on addressing some of the society’s healthcare needs.